Artículos por temáticas

Rationally designed small molecules targeting toxic CAG repeat RNA that causes Huntington's disease (HD) and spinocerebellar ataxia (SCAs).

Khan E, Biswas S, Mishra SK, Mishra R, Samanta S, Mishra A, Tawani A, Kumar A.

Biochimie. 2019 May 8;163:21-32. doi: 10.1016/j.biochi.2019.05.001. [Epub ahead of print]

PGC-1α, Sirtuins and PARPs in Huntington's Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All.

Lloret A, Beal MF.

Neurochem Res. 2019 May 7. doi: 10.1007/s11064-019-02809-1. [Epub ahead of print]

Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington's disease.

Vezzoli E, Caron I, Talpo F, Besusso D, Conforti P, Battaglia E, Sogne E, Falqui A, Petricca L, Verani M, Martufi P, Caricasole A, Bresciani A, Cecchetti O, Rivetti di Val Cervo P, Sancini G, Riess O,

J Clin Invest. 2019 May 6;130. pii: 120616. doi: 10.1172/JCI120616. eCollection 2019 May 6.

New Intrusion Analyses on the CVLT-3: Utility in Distinguishing the Memory Disorders of Alzheimer's versus Huntington's Disease.

Graves LV, Holden HM, Van Etten EJ, Delano-Wood L, Bondi MW, Salmon DP, Corey-Bloom J, Gilbert PE, Delis DC.

J Int Neuropsychol Soc. 2019 May 7:1-6. doi: 10.1017/S1355617719000407. [Epub ahead of print]

Targeting Huntingtin Expression in Patients with Huntington's Disease.

Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schob

N Engl J Med. 2019 May 6. doi: 10.1056/NEJMoa1900907. [Epub ahead of print]

Early neurochemical modifications of monoaminergic systems in the R6/1 mouse model of Huntington's disease.

Puginier E, Bharatiya R, Chagraoui A, Manem J, Cho YH, Garret M, De Deurwaerdère P.

Neurochem Int. 2019 May 2;128:186-195. doi: 10.1016/j.neuint.2019.05.001. [Epub ahead of print]

18F-FDG PET/CT: an unexpected case of Huntington's disease.

Michels S, Buchholz HG, Rosar F, Heinrich I, Hoffmann MA, Schweiger S, Tüscher O, Schreckenberger M.

BMC Neurol. 2019 May 1;19(1):78. doi: 10.1186/s12883-019-1311-9.

Hdac4 interactions in Huntington's Disease viewed through the prism of multiomics.

Federspiel JD, Greco TM, Lum KK, Cristea IM.

Mol Cell Proteomics. 2019 Apr 30. pii: mcp.RA118.001253. doi: 10.1074/mcp.RA118.001253. [Epub ahead of print]

Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease.

Ferrari Bardile C, Garcia-Miralles M, Caron NS, Rayan NA, Langley SR, Harmston N, Rondelli AM, Teo RTY, Waltl S, Anderson LM, Bae HG, Jung S, Williams A, Prabhakar S, Petretto E, Hayden MR, Pouladi MA

Proc Natl Acad Sci U S A. 2019 May 7;116(19):9622-9627. doi: 10.1073/pnas.1818042116. Epub 2019 Apr 23.

Clinical manifestations of homozygote allele carriers in Huntington disease.

Cubo E, Martinez-Horta SI, Santalo FS, Descalls AM, Calvo S, Gil-Polo C, Muñoz I, Llano K, Mariscal N, Diaz D, Gutierrez A, Aguado L, Ramos-Arroyo MA; European HD Network..

Neurology. 2019 Apr 30;92(18):e2101-e2108. doi: 10.1212/WNL.0000000000007147. Epub 2019 Mar 13.

Apathy Is Related to Cognitive Control and Striatum Volumes in Prodromal Huntington's Disease.

Misiura MB, Ciarochi J, Vaidya J, Bockholt J, Johnson HJ, Calhoun VD, Paulsen JS, Turner JA; PREDICT-HD Investigators & Working Group..

J Int Neuropsychol Soc. 2019 May;25(5):462-469. doi: 10.1017/S1355617719000067. Epub 2019 Feb 26.

Apathy Associated With Impaired Recognition of Happy Facial Expressions in Huntington's Disease.

Osborne-Crowley K, Andrews SC, Labuschagne I, Nair A, Scahill R, Craufurd D, Tabrizi SJ, Stout JC; TRACK-HD Investigators..

J Int Neuropsychol Soc. 2019 May;25(5):453-461. doi: 10.1017/S1355617718001224. Epub 2019 Feb 15.

Enhanced striatopallidal gamma-aminobutyric acid (GABA)(A) receptor transmission in mouse models of huntington's disease.

Perez-Rosello T, Gelman S, Tombaugh G, Cachope R, Beaumont V, Surmeier DJ.

Mov Disord. 2019 May;34(5):684-696. doi: 10.1002/mds.27622. Epub 2019 Feb 6.

Induced pluripotent stem cells from Huntington's disease patients: a promising approach to define and correct disease-related alterations.

Fatima A, Gutiérrez-Garcia R, Vilchez D.

Neural Regen Res. 2019 May;14(5):769-770. doi: 10.4103/1673-5374.249223. No abstract available.

Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease.

Sampedro F, Martínez-Horta S, Perez-Perez J, Horta-Barba A, Lopez-Mora DA, Camacho V, Fernández-León A, Gomez-Anson B, Carrió I, Kulisevsky J.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1111-1116. doi: 10.1007/s00259-018-4257-z. Epub 2019 Jan 9.